Healthcare is shrinking, but its not what you think.
Micro and nanobiomedical devices are the future of this industry. These technologies have the power to transform society, markets and even cultures closely related to the healthcare space.A huge breakthrough in the space has been the Lab-on-a-Chip device. The Lab-on-a-Chip device is a collection of miniaturized test wells or microarrays arranged on a solid substrate. Many tests can be performed simultaneously in order to achieve higher output at greater speed. The Global Lab-on-a-Chip Market is increasing and is only expected to grow.
Ostendum, a group of companies focused on the commercialization of the optical detection of micro-organisms, biomarkers, biomolecules and nanoparticles methods, has developed a proprietary Lab-on-a-Chip nanodevice.
The integral technology platform can reach detection limits at least 100 times more sensitive than other LOC devices on market today.
Ostendum focuses their nanodevice applications in early disease diagnostics. Viruses, bacteria and other microorganisms are not the only things that can be detected. Biomarkers, and biomolecules can be identified and targeted with Ostendum’s technology. Portability, easy-handling, and minimal power requirement, make Ostendum’s nanodevice technology suitable for a broad spectrum of applications and industries. The LOC device can be used either on a medical site or at home.
Beyond its strong technical support, Ostendum has demonstrated solid business development and ROI. The company has partnered with the University Twente, the Research Institute for Nanotechnology, and others enabling the company to speed development of low cost disposable chips.
For their technology innovation and continued market success Frost & Sullivan is proud to present the 2013 European Technology Innovation Leadership Award in Lab-on-a-Chip Nanodevices to Ostendum R&D BV.